Conduit Pharmaceuticals reports advancements in lupus studies and trial designs. The Company partnered with Charles River Laboratories to conduct preclinical studies of glucokinase inhibitors for autoimmune disease with a focus on lupus. Significant advancements have been achieved in preclinical studies for its therapy, AZD5658. The research seeks to evaluate the drug’s effect on disease progression in a widely recognized lupus model, employing standard measures of disease advancement. Additionally, the study will examine the drug’s influence on inflammatory biomarkers and pro-inflammatory cytokine levels, with particular attention to Treg immunoregulation.
Additionally, phase 2 trial design of AZD1656 targeting systemic lupus erythematosus with nephritis and ANCA-associated vasculitis is underway. AZD1656 is a HK-4 glucokinase activator which is an anti-diabetic drug designed to regulate blood sugars and enhance beta cell function in people with diabetes. This study will be conducted at a single location, utilizing a double-blind, placebo-controlled design.
Results of the Charles River Laboratories preclinical studies are expected in Q2 this year. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
This post was originally published on this site